Neurocrine Biosciences, Inc. (NBIX)
NASDAQ
Closed
Oct 9, 2026
Day's Range
140.0252 wk Range
122.14Overview - NBIX - Neurocrine Biosciences, Inc.
Key Statistics
Valuation
Enterprise Value
14.62B
P/E (Trailing)
‪20.93‬
P/E (Forward)
‪12.05‬
PEG Ratio
‪0.67‬
Price / Sales (TTM)
‪4.31‬
Price / Book
‪3.93‬
EV / EBITDA
‪16.01‬
Profitability
Gross Margin
‪97.58%‬
Profit Margin
‪20.91%‬
Operating Margin
‪22.19%‬
Return on Assets
‪11.70%‬
Return on Equity
‪22.08%‬
Ownership
Shares Outstanding
101.60M
Float
100.36M
Short % of Shares Outstanding
‪6.34%‬
Held by Insiders
‪1.06%‬
Held by Institutions
‪102.81%‬
Price stats
Beta
‪0.38‬
50-Day Avg
‪155.65‬
200-Day Avg
‪147.27‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
29 analysts
Average price target
‪$ 211.57‬Shariah Compliance
Report Date: Feb 15, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - NBIX - Neurocrine Biosciences, Inc.
Peers - NBIX - Neurocrine Biosciences, Inc.
Peer Comparison
Compared with companies in Drug Manufacturers - Specialty & Generic listed on NASDAQ.
- NBIXNASDAQNeurocrine Biosciences, Inc.14.55BMarket Cap+2.62%52-week change20.93P/E (Trailing)‪20.91%‬Profit Margin
- AMRXNASDAQAmneal Pharmaceuticals, Inc.7.07BMarket Cap+48.03%52-week change42.29P/E (Trailing)‪5.04%‬Profit Margin
- ALKSNASDAQAlkermes plc7.00BMarket Cap+25.77%52-week change109.87P/E (Trailing)‪3.96%‬Profit Margin
- LNTHNASDAQLantheus Holdings Inc.6.52BMarket Cap+47.28%52-week change23.91P/E (Trailing)‪17.69%‬Profit Margin
- KNSANASDAQKiniksa Pharmaceuticals International, plc Class A Ordinary Shares5.83BMarket Cap+49.48%52-week change76.56P/E (Trailing)‪9.59%‬Profit Margin
- DIODNASDAQDiodes Incorporated4.43BMarket Cap+49.74%52-week change57.61P/E (Trailing)‪5.26%‬Profit Margin
- INDVNASDAQIndivior Pharmaceuticals, Inc.4.21BMarket Cap+36.35%52-week change12.68P/E (Trailing)‪26.74%‬Profit Margin
Profile Summary - NBIX - Neurocrine Biosciences, Inc.
About
Neurocrine Biosciences, Inc. is a neuroscience-focused biopharmaceutical company that discovers, develops, and commercializes medicines for neurological, neuroendocrine, and neuropsychiatric disorders. Its current portfolio includes treatments for movement disorders such as tardive dyskinesia and Huntington’s disease…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
